









市場行情
/
股票
/
nasdaq-iron
/

Disc Medicine Inc

IRON

80.330USD

-0.100-0.12%

收盤 12/26, 16:00（美東）報價延遲15分鐘

2.81B總市值

虧損本益比TTM



Disc Medicine Inc

80.330

-0.100-0.12%

概覽公司財務分析

概覽

公司

財務

分析

關於 Disc Medicine Inc 公司

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Disc Medicine Inc簡介



公司代碼IRON

公司名稱Disc Medicine Inc

上市日期Aug 12, 2020

CEOQuisel (John D)

員工數量84

證券類型Ordinary Share

年結日Aug 12

公司地址321 Arsenal Street, Suite 101

城市WATERTOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02472

電話16176749274

網址https://www.discmedicine.com/

公司代碼IRON

上市日期Aug 12, 2020

CEOQuisel (John D)

Disc Medicine Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Rahul Khara, Pharm.D.

Chief Legal Officer

36.87K

+162.73%

Ms. Pamela Stephenson

Chief Commercial Officer

6.03K

-91.33%

Mr. Jonathan Yu

Chief Operating Officer

Mr. William White, J.D.

Independent Director

Dr. Donald W. (Don) Nicholson, Ph.D.

Executive Chairman of the Board

Dr. Liam T. Ratcliffe, M.D., Ph.D.

Independent Director

Ms. Jean M. Franchi, CPA

Chief Financial Officer

-100.00%

Dr. William Savage, M.D., Ph.D.

Chief Medical Officer

Dr. Georges Gemayel, Ph.D.

Director

Mr. Kevin J. Bitterman, Ph.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Rahul Khara, Pharm.D.

Chief Legal Officer

36.87K

+162.73%

Ms. Pamela Stephenson

Chief Commercial Officer

6.03K

-91.33%

Mr. Jonathan Yu

Chief Operating Officer

Mr. William White, J.D.

Independent Director

Dr. Donald W. (Don) Nicholson, Ph.D.

Executive Chairman of the Board

Dr. Liam T. Ratcliffe, M.D., Ph.D.

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

10.43%

Access Industries, Inc.

7.46%

BlackRock Institutional Trust Company, N.A.

4.49%

RA Capital Management, LP

4.18%

Atlas Venture

4.01%

其他

69.43%

持股股東

佔比

Fidelity Management & Research Company LLC

10.43%

Access Industries, Inc.

7.46%

BlackRock Institutional Trust Company, N.A.

4.49%

RA Capital Management, LP

4.18%

Atlas Venture

4.01%

其他

69.43%

股東類型

持股股東

佔比

Investment Advisor

38.73%

Investment Advisor/Hedge Fund

16.51%

Hedge Fund

15.63%

Venture Capital

9.99%

Private Equity

8.55%

Corporation

7.46%

Research Firm

2.13%

Sovereign Wealth Fund

0.76%

Individual Investor

0.43%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

341

35.08M

92.93%

-3.22M

2025Q2

344

37.34M

107.82%

+1.72M

2025Q1

342

37.53M

108.38%

+1.77M

2024Q4

318

30.70M

90.70%

-5.11M

2024Q3

302

32.06M

106.93%

-4.30M

2024Q2

292

32.17M

107.84%

+2.52M

2024Q1

275

26.60M

108.28%

-1.06M

2023Q4

248

24.37M

101.48%

-1.80M

2023Q3

211

23.78M

99.79%

-259.52K

2023Q2

190

22.86M

100.53%

+3.93M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

3.08M

8.87%

+31.14K

+1.02%

Jun 30, 2025

Access Industries, Inc.

3.56M

10.24%

Feb 27, 2025

BlackRock Institutional Trust Company, N.A.

1.71M

4.93%

-38.49K

-2.20%

Jun 30, 2025

RA Capital Management, LP

1.58M

4.54%

Jun 30, 2025

Atlas Venture

2.15M

6.18%

-235.47K

-9.88%

Aug 14, 2025

The Vanguard Group, Inc.

1.39M

+90.73K

+6.98%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

1.65M

4.76%

-100.00K

-5.70%

Jun 30, 2025

OrbiMed Advisors, LLC

1.42M

4.07%

Jun 30, 2025

Wellington Management Company, LLP

1.43M

4.12%

-911.41K

-38.89%

Jun 30, 2025

T. Rowe Price Associates, Inc.

1.49M

4.3%

+155.07K

+11.58%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ALPS Medical Breakthroughs ETF

1.25%

Virtus LifeSci Biotech Clinical Trials ETF

1.11%

JPMorgan Healthcare Leaders ETF

0.92%

State Street SPDR S&P Biotech ETF

0.79%

Direxion Daily S&P Biotech Bull 3X Shares

0.48%

JPMorgan Fundamental Data Science Small Core ETF

0.4%

ProShares Ultra Nasdaq Biotechnology

0.39%

Invesco Nasdaq Biotechnology ETF

0.29%

iShares Health Innovation Active ETF

0.27%

iShares Biotechnology ETF

0.18%

ALPS Medical Breakthroughs ETF

佔比1.25%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.11%

JPMorgan Healthcare Leaders ETF

佔比0.92%

State Street SPDR S&P Biotech ETF

佔比0.79%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.48%

JPMorgan Fundamental Data Science Small Core ETF

佔比0.4%

ProShares Ultra Nasdaq Biotechnology

佔比0.39%

Invesco Nasdaq Biotechnology ETF

佔比0.29%

iShares Health Innovation Active ETF

佔比0.27%

iShares Biotechnology ETF

佔比0.18%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

公告日期

類型

比率

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

常見問題

Disc Medicine Inc的前五大股東是誰？



Disc Medicine Inc的前五大股東如下：
Fidelity Management & Research Company LLC
持有股份：3.08M
佔總股份比例：8.87%。
Access Industries, Inc.
持有股份：3.56M
佔總股份比例：10.24%。
BlackRock Institutional Trust Company, N.A.
持有股份：1.71M
佔總股份比例：4.93%。
RA Capital Management, LP
持有股份：1.58M
佔總股份比例：4.54%。
Atlas Venture
持有股份：2.15M
佔總股份比例：6.18%。